Sugi Predict

Sugi Predict / Compounds / SCHEMBL436674

SCHEMBL436674

SCHEMBL436674

Cc1ccc(S(=O)(=O)N2CCCC2)cc1

nearest known ligand 0.89

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 3/20 0.89
▸ ALDH1A1 P00352 4/20 0.89
▸ HTT P42858 2/20 0.89
▸ POLB P06746 1/20 0.89
▸ KMT2A Q03164 4/20 0.83
▸ MEN1 O00255 3/20 0.83
▸ SMN1; SMN2 Q16637 1/20 0.83
▸ USP2 O75604 1/20 0.76
▸ HSD17B10 Q99714 1/20 0.73
▸ LMNA P02545 2/20 0.72
▸ TDP1 Q9NUW8 1/20 0.69
▸ KDM4E B2RXH2 1/20 0.68
▸ GAA P10253 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18484219 0.98 KMT2A (0.86) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL31476293 0.98 ALDH1A1 (0.92) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL3812763 0.98 KMT2A (0.86) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL7645597 0.98 KMT2A (0.86) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL15945283 0.98 KMT2A (0.86) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL5564371 0.98 KMT2A (0.86) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL10409988 0.96 PKM (0.96) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL4102676 0.96 PKM (0.96) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL8193968 0.96 PKM (0.96) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL7953663 0.94 PKM (1.00) PKMALDH1A1HTTPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103588694-A Synthetic method of darifenacin intermediate Shanghai new hualian pharmaceutical co ltd 2014-02-19 — — CN claimed
US-20250025854-A1 EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF ExxonMobil Technology and Engineering Company 2025-01-23 — — US disclosed
US-20250025855-A1 EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF ExxonMobil Technology and Engineering Company 2025-01-23 — — US disclosed
CN-118685793-A Synthesis method of thio-N-heterocyclic compound 南阳师范学院 2024-09-24 — — CN disclosed
CN-113165893-B EMM-41 compositions, methods of manufacture and uses thereof 埃克森美孚科技工程公司 2024-06-11 — — CN disclosed
US-20230286973-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2023-09-14 — — US disclosed
US-20230286973-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2023-09-14 — — US disclosed
CN-111491891-B EMM-31 material, method and use thereof 埃克森美孚科技工程公司 2023-07-04 — — CN disclosed
CN-108290749-B Novel synthetic crystalline EMM-28 material, its preparation and use 埃克森美孚科技工程公司 2022-06-24 — — CN disclosed
CN-109020924-B Method for synthesizing benzene sulfonamide compound from benzene sulfonyl chloride compound and secondary amine through metal-free catalysis 湖南农业大学 2022-05-13 — — CN disclosed
US-7253158-B2 Sulfonamides HOFFMANN-LA ROCHE INC. (US) 2007-08-07 — — US disclosed
WO-2007076158-A2 PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-07-05 — — WO disclosed
US-6995182-B2 1-sulfonyl pyrrolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-02-07 — — US disclosed
US-6589978-B2 Therapy for nervous system disorders HOFFMAN-LA ROCHE INC. 2003-07-08 — — US disclosed
US-6432948-B1 ANTIULCER AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2002-08-13 — — US disclosed
EP-0946176-B1 THE USE OF 7-(2-OXA-5,8-DIAZABICYCLO 4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES BAYER AG (DE) 2002-03-27 — — EP disclosed
US-6133260-A Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases BAYER AKTIENGESELLSCHAFT (DE) 2000-10-17 — — US disclosed
EP-0946176-A1 THE USE OF 7-(2-OXA-5,8-DIAZABICYCLO 4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES BAYER AG (DE) 1999-10-06 — — EP disclosed
WO-1998026779-A1 THE USE OF 7-(2-OXA-5,8-DIAZABICYCLO[4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES BAYER AKTIENGESELLSCHAFT (DE) 1998-06-25 — — WO disclosed
EP-0505377-A1 MUSCARINIC RECEPTOR ANTAGONISTS. PFIZER LTD (GB) 1992-09-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250025855-A1 EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF CD14, CD68, MASP2 PKM 4105/4885ALDH1A1 4549/4885HTT 2490/4885
US-20230286973-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G PKM 4202/4885ALDH1A1 4729/4885HTT 2217/4885
US-20250025854-A1 EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF CD14, CD68, MASP2 PKM 4105/4885ALDH1A1 4549/4885HTT 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.